Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on X:
“Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia’s Landmark Tumor-Agnostic Immunotherapy Reimbursement, Journal of Clinical Oncology. Learn more.”
Razelle Kurzrock, Chief Medical Officer of the WIN Consortium and Director of the Center for Precision Oncology and Rare Cancers at the Medical College of Wisconsin, added:
“The first totally agnostic approvals. Because we don’t know everything about IO biomarkers. And because our DART study showed that a subset of patients with refractory rare cancers achieve long-term disease-free remissions (aka cures).”
Title: Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia’s Landmark Tumor-Agnostic Immunotherapy Reimbursement
Authors: Vivek Subbiah, Razelle Kurzrock
Read the full article here.
You may also be interested in: Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia Expands Immunotherapy Access
